M. Giurescu

发表

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.

G. Lenz, A. Santoro, A. Nagler, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following chemotherapy

S. Luoh, G. Hortobagyi, L. Vahdat, 2010, Breast Cancer Research and Treatment.

Preliminary results of a phase II study of single agent Bay 80-6946, a Novel PI3K inhibitor, in patients with relapsed/refractory, indolent or aggressive lymphoma.

P. Zinzani, M. Dreyling, B. Childs, 2013, Clinical advances in hematology & oncology : H&O.

Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors.

E. Thiel, K. Possinger, P. Schmid, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Sagopilone (ZK-EPO): from a natural product to a fully synthetic clinical development candidate

U. Klar, J. Hoffmann, M. Giurescu, 2008, Expert opinion on investigational drugs.

The clinical efficacy of progesterone antagonists in breast cancer

W. Jonat, M. Giurescu, 2002 .

Abstract CT215: CHRONOS-1: Open-label, uncontrolled phase II trial of intravenous phosphatidylinositol-3 kinase alpha/delta inhibitor copanlisib in patients with relapsed, indolent Non-Hodgkin's lymphomas (iNHL)

M. Dreyling, B. Childs, L. Cupit, 2015 .

Sagopilone (ZK-EPO): from a natural product to a fully synthetic clinical development candidate.

U. Klar, J. Hoffmann, M. Giurescu, 2008, Expert opinion on investigational drugs.

Sagopilone(ZK-EPO):froma naturalproducttoafullysynthetic clinicaldevelopmentcandidate

U. Klar, J. Hoffmann, M. Giurescu, 2008 .

Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer

P. Ghatage, P. Celano, S. McMeekin, 2011, British Journal of Cancer.

Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial

E. Thiel, W. Voigt, H. Schmoll, 2009, British Journal of Cancer.

Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma

P. Zinzani, D. Cunningham, G. Verhoef, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT B‐CELL LYMPHOMA (CHRONOS‐1)

G. Lenz, A. Santoro, A. Nagler, 2017 .

Phase 2A Study of Copanlisib, a Novel PI3K Inhibitor, in Patients with Indolent Lymphoma

D. Cunningham, M. Dreyling, B. Childs, 2014 .

Phase-I study of sagopilone in combination with cisplatin in chemotherapy-naive patients with metastasised small-cell lung cancer.

T. Gauler, R. Huber, N. Frickhofen, 2013, European journal of cancer.

A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer.

M. Gore, G. Jayson, G. Rustin, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer

M. Teufel, B. Melichar, J. Jassem, 2017, Targeted Oncology.

Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium

D. Smith, Y. Wang, J. Wang, 2012, British Journal of Cancer.

Phase II study of first-line sagopilone combined with prednisone in patients with metastatic castration-resistant prostate cancer (CRPC).

D. Smith, Y. Wang, J. Wang, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of the novel epothilone sagopilone (ZK-EPO) in combination with cisplatin as first-line therapy in patients with extensive-disease small-cell lung cancer (ED-SCLC)

T. Gauler, M. Schuler, F. Gamarra, 2008 .

Influence of treatment with onapristone on the IGF-system in breast cancer patients

P. Lønning, W. Jonat, J. Holly, 1998, The Journal of Steroid Biochemistry and Molecular Biology.

A phase I/II study of the MEK inhibitor BAY 86-9766 (BAY) in combination with gemcitabine (GEM) in patients with nonresectable, locally advanced or metastatic pancreatic cancer (PC): Phase I dose-escalation results.

V. Heinemann, J. Jassem, U. Martens, 2012 .

A phase I study of the novel, third generation epothilone ZK-EPO in patients with advanced solid tumors

E. Thiel, K. Possinger, P. Schmid, 2005 .

6568 POSTER Phase II trial of the novel epothilone ZK-EPO as second-line therapy in patients with stage IIIB or stage IV non-small-cell lung cancer

U. Gatzemeier, C. Eschbach, M. Reck, 2007 .

Phase II study of refametinib (BAY 86-9766), an allosteric dual MEK 1/2 inhibitor, and gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer.

M. Teufel, V. Heinemann, B. Melichar, 2014 .

Phase II study of sagopilone (ZK-Epo) in patients with recurrent metastatic breast cancer (MBC).

S. Luoh, G. Hortobagyi, L. Vahdat, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.

G. Lenz, A. Santoro, A. Nagler, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.